Zynerba Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Zynerba Pharmaceuticals hat ein Gesamteigenkapital von $29.0M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $40.5M bzw. $11.5M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$35.97m
Eigenkapital	US$29.02m
Gesamtverbindlichkeiten	US$11.46m
Gesamtvermögen	US$40.48m

Jüngste Berichte zur Finanzlage

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Mar 01

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 11

Recent updates

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Mar 01

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 11

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Oct 06

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

Aug 10

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Jul 22

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Jul 21

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Mar 23

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Dec 02

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

May 27

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Dec 17

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 23

Zynerba Pharmaceuticals EPS beats by $0.12

Nov 09

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

Oct 29

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ZYNEDie kurzfristigen Aktiva des Unternehmens ($39.3M) übersteigen seine kurzfristigen Passiva ($11.5M).

Langfristige Verbindlichkeiten: ZYNE hat keine langfristigen Verbindlichkeiten.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ZYNE ist schuldenfrei.

Schulden abbauen: ZYNE hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: ZYNE auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: ZYNE hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 0.5% pro Jahr abnimmt

Zynerba Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Recent updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

Price target decreased by 78% to US$1.26

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Price target increased by 7.9% to US$5.80

Forecast to breakeven in 2025

Price target increased by 30% to US$7.00

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$5.44

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Price target increased to US$8.33

Insufficient new directors

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Price target decreased to US$6.95

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Price target decreased to US$6.95

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

New 90-day high: US$5.08

New 90-day low: US$3.27

Zynerba Pharmaceuticals, Inc. Provides Regulatory Update on Zygel™ in Fragile X Syndrome

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

New 90-day high: US$3.88

Zynerba Pharmaceuticals EPS beats by $0.12

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

New 90-day low: US$3.23

Zynerba Pharmaceuticals, Inc. Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

Price target raised to US$10.00

First half earnings released

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from Russell Small Cap Completeness Index

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from Russell 3000 Growth Index

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz